Amicus Therapeutics (FOLD), Glaxo (GSK) Report Study 011 Did Not Achieve Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Downgrades Amicus Therapeutics (FOLD) to Underperform, Sees Another 50% Slide
December 21, 2012 9:39 AM ESTAmicus Therapeutics (NASDAQ: FOLD) fell 47 percent on Thursday after its ongoing migalastat monotherapy Phase III trial did not meet the primary and a pre-defined secondary endpoint, however, one analyst thinks it goes down another 50 percent from here.
Wedbush downgraded Amicus from Neutral to... More
Leerink Swann Cuts PT on Amicus Therapeutics (FOLD), But Remains Overall Bullilsh
December 20, 2012 12:25 PM ESTLeerink Swann cut its price target on Amicus Therapeutics (NASDAQ: FOLD) from $9 to $5 after the company reported Wednesday that Phase III study ('011) of Amigal monotherapy in Fabry disease missed its primary and secondary endpoints. However, they maintained an Outperform rating.... More
Amicus (FOLD) Slammed Following Study 011 Update
December 19, 2012 4:36 PM ESTAmicus Therapeutics (Nasdaq: FOLD) shares are getting slammed in late trading following an update on Study 011. Amicus said the study missed its primary endpoint.
Shares are down about 50 percent on resumption.... More
Amicus Therapeutics (FOLD) to resume trading at 4:30PM ET
December 19, 2012 4:27 PM ESTAmicus Therapeutics, Inc. (NASDAQ: FOLD) to resume trading at 4:30PM ET after reporting that a study failed to show statistical benefit.... More
Amicus Therapeutics (FOLD) halted, news pending
December 19, 2012 4:00 PM ESTAmicus Therapeutics, Inc. (NASDAQ: FOLD) halted, news pending... More
